NCT00003109View on ClinicalTrials.gov

Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

December 31, 1997

Primary Completion Date

October 31, 2000

Study Completion Date

January 31, 2001

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

irinotecan hydrochloride

DRUG

raltitrexed

Trial Locations (1)

19111

Fox Chase Cancer Center, Philadelphia

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fox Chase Cancer Center

OTHER

NCT00003109 - Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors | Biotech Hunter | Biotech Hunter